Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12520631,24-hour AUC ratio,"In multiple doses, the 24-hour AUC ratio for all comparisons of nizatidine CR 150 mg bid, nizatidine CR 300 mg daily, and nizatidine IR 150 mg bid was between 97% and 99%.",Pharmacokinetics and pharmacodynamics of a novel nizatidine controlled-release formulation in healthy subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520631/),%,97,3125,DB00585,Nizatidine
,12520631,24-hour AUC ratio,"In multiple doses, the 24-hour AUC ratio for all comparisons of nizatidine CR 150 mg bid, nizatidine CR 300 mg daily, and nizatidine IR 150 mg bid was between 97% and 99%.",Pharmacokinetics and pharmacodynamics of a novel nizatidine controlled-release formulation in healthy subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520631/),%,99,3126,DB00585,Nizatidine
,2903807,t 1/2,"All 'old' and 'new' H2-receptor blockers are eliminated relatively rapidly (t 1/2 ranges from 1.5 to 4 hours), mainly by the renal route (glomerular filtration and tubular secretion).",Newer H2-receptor antagonists. Clinical pharmacokinetics and drug interaction potential. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903807/),h,1.5 to 4,6283,DB00585,Nizatidine
,22147077,dose,"The only variable factor, the dasatinib dose-adjusted AUC(0-4) for patients administered an H2RA or PPI, was significantly lower than for patients not administered an acid suppressant (median (quartile 1-quartile 3) values: 1.47 (0.79-2.29) versus 3.51 (2.50-5.45) ng h/mL/mg, respectively, P = 0.0008).",Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22147077/),[h·ng] / [mg·ml],1.47,11921,DB00585,Nizatidine
,22147077,AUC(0-4),"The only variable factor, the dasatinib dose-adjusted AUC(0-4) for patients administered an H2RA or PPI, was significantly lower than for patients not administered an acid suppressant (median (quartile 1-quartile 3) values: 1.47 (0.79-2.29) versus 3.51 (2.50-5.45) ng h/mL/mg, respectively, P = 0.0008).",Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22147077/),[h·ng] / [mg·ml],1.47,11922,DB00585,Nizatidine
,22147077,AUC(0-4),"The only variable factor, the dasatinib dose-adjusted AUC(0-4) for patients administered an H2RA or PPI, was significantly lower than for patients not administered an acid suppressant (median (quartile 1-quartile 3) values: 1.47 (0.79-2.29) versus 3.51 (2.50-5.45) ng h/mL/mg, respectively, P = 0.0008).",Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22147077/),[h·ng] / [mg·ml],3.51,11923,DB00585,Nizatidine
,15085026,maximum plasma concentration,"Dose-normalized exposure estimates revealed no apparent age dependence; however, maximum plasma concentration (298.5 +/- 100.7 v 552.8 +/- 152.4 ng/mL per mg/kg dose) and AUC0-infinity (954.4 +/- 379.8 v 1,573.0 +/- 347.4 ng*hour/mL per mg/kg dose) were reduced in extemporaneous formulations in apple juice.",Developmental pharmacokinetics and pharmacodynamics of nizatidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15085026/),[ng] / [dose·kg·mg·ml],298.5,19711,DB00585,Nizatidine
,15085026,maximum plasma concentration,"Dose-normalized exposure estimates revealed no apparent age dependence; however, maximum plasma concentration (298.5 +/- 100.7 v 552.8 +/- 152.4 ng/mL per mg/kg dose) and AUC0-infinity (954.4 +/- 379.8 v 1,573.0 +/- 347.4 ng*hour/mL per mg/kg dose) were reduced in extemporaneous formulations in apple juice.",Developmental pharmacokinetics and pharmacodynamics of nizatidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15085026/),[ng] / [dose·kg·mg·ml],552.8,19712,DB00585,Nizatidine
,15085026,AUC0-infinity,"Dose-normalized exposure estimates revealed no apparent age dependence; however, maximum plasma concentration (298.5 +/- 100.7 v 552.8 +/- 152.4 ng/mL per mg/kg dose) and AUC0-infinity (954.4 +/- 379.8 v 1,573.0 +/- 347.4 ng*hour/mL per mg/kg dose) were reduced in extemporaneous formulations in apple juice.",Developmental pharmacokinetics and pharmacodynamics of nizatidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15085026/),[h·ng] / [kg·mg·ml],954.4,19713,DB00585,Nizatidine
,15085026,AUC0-infinity,"Dose-normalized exposure estimates revealed no apparent age dependence; however, maximum plasma concentration (298.5 +/- 100.7 v 552.8 +/- 152.4 ng/mL per mg/kg dose) and AUC0-infinity (954.4 +/- 379.8 v 1,573.0 +/- 347.4 ng*hour/mL per mg/kg dose) were reduced in extemporaneous formulations in apple juice.",Developmental pharmacokinetics and pharmacodynamics of nizatidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15085026/),[h·ng] / [kg·mg·ml],"1,573.0",19714,DB00585,Nizatidine
,1673880,oral bioavailability,The mean oral bioavailability for the H2-antagonists ranges from 50 to 70%.,Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673880/),%,50 to 70,45683,DB00585,Nizatidine
,1673880,terminal half-life,"All of the H2-antagonists are eliminated quite rapidly, with a terminal half-life of 1 to 3h and a total body clearance of 24 to 48 L/h.",Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673880/),h,1 to 3,45684,DB00585,Nizatidine
,1673880,total body clearance,"All of the H2-antagonists are eliminated quite rapidly, with a terminal half-life of 1 to 3h and a total body clearance of 24 to 48 L/h.",Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673880/),[l] / [h],24 to 48,45685,DB00585,Nizatidine
,1673880,renal clearances,"Elimination is mainly attributable to renal excretion, with renal clearances ranging from 13.8 to 30 L/h.",Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673880/),[l] / [h],13.8 to 30,45686,DB00585,Nizatidine
,2905991,elimination half-life,The elimination half-life of ibuprofen on placebo was 2.04 h.,Do nizatidine and cimetidine interact with ibuprofen? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905991/),h,2.04,61733,DB00585,Nizatidine
,2905991,elimination half-life,The elimination half-life of nizatidine on ibuprofen was 1.72 h and that of cimetidine was 3.54 h.,Do nizatidine and cimetidine interact with ibuprofen? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905991/),h,1.72,61734,DB00585,Nizatidine
,2905991,elimination half-life,The elimination half-life of nizatidine on ibuprofen was 1.72 h and that of cimetidine was 3.54 h.,Do nizatidine and cimetidine interact with ibuprofen? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905991/),h,3.54,61735,DB00585,Nizatidine
,12079004,concentration,"The plasma nizatidine concentration was highest (2420.0+/-192.4 and 996.0+/-54.6 ng mL(-1)) in the sample taken 1 h after administration of 300 mg nizatidine (high dose) and 150mg nizatidine (low dose), respectively.",Effect of nizatidine on paracetamol and its metabolites in human plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12079004/),[ng] / [ml],2420.0,67405,DB00585,Nizatidine
,12079004,concentration,"The plasma nizatidine concentration was highest (2420.0+/-192.4 and 996.0+/-54.6 ng mL(-1)) in the sample taken 1 h after administration of 300 mg nizatidine (high dose) and 150mg nizatidine (low dose), respectively.",Effect of nizatidine on paracetamol and its metabolites in human plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12079004/),[ng] / [ml],996.0,67406,DB00585,Nizatidine
,12079004,total area under the plasma paracetamol concentration-time curve from 0 to 180 min,"The total area under the plasma paracetamol concentration-time curve from 0 to 180 min (2361.5+/-146.4 and 2085.75+/-73.5 microg min mL(-1)) significantly increased after coadministration of nizatidine (high and low doses), respectively (P < 0.01 vs placebo).",Effect of nizatidine on paracetamol and its metabolites in human plasma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12079004/),[min·μg] / [ml],2361.5,67407,DB00585,Nizatidine
,12079004,total area under the plasma paracetamol concentration-time curve from 0 to 180 min,"The total area under the plasma paracetamol concentration-time curve from 0 to 180 min (2361.5+/-146.4 and 2085.75+/-73.5 microg min mL(-1)) significantly increased after coadministration of nizatidine (high and low doses), respectively (P < 0.01 vs placebo).",Effect of nizatidine on paracetamol and its metabolites in human plasma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12079004/),[min·μg] / [ml],2085.75,67408,DB00585,Nizatidine
,2897890,elimination half-life,After intravenous administration the elimination half-life increased from 1.5 +/- 0.2 hours in normal volunteers to 6.9 +/- 3.3 hours in patients with renal failure.,Nizatidine disposition in subjects with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897890/),h,1.5,68450,DB00585,Nizatidine
,2897890,elimination half-life,After intravenous administration the elimination half-life increased from 1.5 +/- 0.2 hours in normal volunteers to 6.9 +/- 3.3 hours in patients with renal failure.,Nizatidine disposition in subjects with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897890/),h,6.9,68451,DB00585,Nizatidine
,2897890,plasma clearance,The plasma clearance decreased from 0.59 +/- 0.07 L/kg/hr in normal volunteers to 0.14 +/- 0.02 L/kg/hr in patients with renal failure.,Nizatidine disposition in subjects with normal and impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897890/),[l] / [h·kg],0.59,68452,DB00585,Nizatidine
,2897890,plasma clearance,The plasma clearance decreased from 0.59 +/- 0.07 L/kg/hr in normal volunteers to 0.14 +/- 0.02 L/kg/hr in patients with renal failure.,Nizatidine disposition in subjects with normal and impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897890/),[l] / [h·kg],0.14,68453,DB00585,Nizatidine
,2897890,bioavailability,Nizatidine bioavailability was nearly 100% in normal volunteers but decreased to 75% in patients with renal failure.,Nizatidine disposition in subjects with normal and impaired renal function. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897890/),%,100,68454,DB00585,Nizatidine
,2897890,bioavailability,Nizatidine bioavailability was nearly 100% in normal volunteers but decreased to 75% in patients with renal failure.,Nizatidine disposition in subjects with normal and impaired renal function. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897890/),%,75,68455,DB00585,Nizatidine
,2897890,volume of distribution,The volume of distribution was 1.3 +/- 0.1 L/kg in normal volunteers and was not different in patients with renal failure.,Nizatidine disposition in subjects with normal and impaired renal function. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897890/),[l] / [kg],1.3,68456,DB00585,Nizatidine
,2897890,protein binding,Nizatidine protein binding was about 30% in normal and uremic plasma.,Nizatidine disposition in subjects with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897890/),%,30,68457,DB00585,Nizatidine
greater,2895125,basal secretion,"Nizatidine was studied in six high-acid-secretor (basal secretion, greater than or equal to 5 mEq/hr) male volunteers in a randomized, double-blind, nonbalanced, cross-over, placebo and standard drug-controlled study.",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [h],5,79356,DB00585,Nizatidine
,2895125,Nocturnal,"Nocturnal acid output was significantly reduced (P less than .01) by all doses of nizatidine (36 +/- 22, 36 +/- 31, and 26 +/- 20 mEq) with 75 mg, 150 mg and 300 mg, respectively, and also by cimetidine (43 +/- 39 mEq) as compared with placebo (101 +/- 61 mEq).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),meq,36,79357,DB00585,Nizatidine
,2895125,Nocturnal,"Nocturnal acid output was significantly reduced (P less than .01) by all doses of nizatidine (36 +/- 22, 36 +/- 31, and 26 +/- 20 mEq) with 75 mg, 150 mg and 300 mg, respectively, and also by cimetidine (43 +/- 39 mEq) as compared with placebo (101 +/- 61 mEq).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),meq,36,79358,DB00585,Nizatidine
,2895125,Nocturnal,"Nocturnal acid output was significantly reduced (P less than .01) by all doses of nizatidine (36 +/- 22, 36 +/- 31, and 26 +/- 20 mEq) with 75 mg, 150 mg and 300 mg, respectively, and also by cimetidine (43 +/- 39 mEq) as compared with placebo (101 +/- 61 mEq).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),meq,43,79359,DB00585,Nizatidine
,2895125,acid output,"Nocturnal acid output was significantly reduced (P less than .01) by all doses of nizatidine (36 +/- 22, 36 +/- 31, and 26 +/- 20 mEq) with 75 mg, 150 mg and 300 mg, respectively, and also by cimetidine (43 +/- 39 mEq) as compared with placebo (101 +/- 61 mEq).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),meq,36,79360,DB00585,Nizatidine
,2895125,acid output,"Nocturnal acid output was significantly reduced (P less than .01) by all doses of nizatidine (36 +/- 22, 36 +/- 31, and 26 +/- 20 mEq) with 75 mg, 150 mg and 300 mg, respectively, and also by cimetidine (43 +/- 39 mEq) as compared with placebo (101 +/- 61 mEq).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),meq,36,79361,DB00585,Nizatidine
,2895125,acid output,"Nocturnal acid output was significantly reduced (P less than .01) by all doses of nizatidine (36 +/- 22, 36 +/- 31, and 26 +/- 20 mEq) with 75 mg, 150 mg and 300 mg, respectively, and also by cimetidine (43 +/- 39 mEq) as compared with placebo (101 +/- 61 mEq).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),meq,26,79362,DB00585,Nizatidine
,2895125,acid output,"Nocturnal acid output was significantly reduced (P less than .01) by all doses of nizatidine (36 +/- 22, 36 +/- 31, and 26 +/- 20 mEq) with 75 mg, 150 mg and 300 mg, respectively, and also by cimetidine (43 +/- 39 mEq) as compared with placebo (101 +/- 61 mEq).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),meq,43,79363,DB00585,Nizatidine
,2895125,acid output,"Nocturnal acid output was significantly reduced (P less than .01) by all doses of nizatidine (36 +/- 22, 36 +/- 31, and 26 +/- 20 mEq) with 75 mg, 150 mg and 300 mg, respectively, and also by cimetidine (43 +/- 39 mEq) as compared with placebo (101 +/- 61 mEq).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),meq,101,79364,DB00585,Nizatidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [2],14,79365,DB00585,Nizatidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [2],9,79366,DB00585,Nizatidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [2],5,79367,DB00585,Nizatidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),m,50,79368,DB00585,Nizatidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),m,57,79369,DB00585,Nizatidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),m,50,79370,DB00585,Nizatidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [2],65,79371,DB00585,Nizatidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [2],78,79372,DB00585,Nizatidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [2],71,79373,DB00585,Nizatidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [2],25,79374,DB00585,Nizatidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [2],27,79375,DB00585,Nizatidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [2],31,79376,DB00585,Nizatidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [2],81,79377,DB00585,Nizatidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [2],76,79378,DB00585,Nizatidine
,2895125,acid secretion,"Nizatidine also significantly reduced meal-stimulated acid secretion at breakfast (14 +/- 9, 9 +/- 7, and 5 +/- 6 mEq/2 hours with 75 mg, 150 mg, and 300 mg, respectively, P less than .01), at lunch (50 +/- 22, 57 +/- 22 and 50 +/- 35 mEq/2 hours, P less than .05) but did not have any effect at dinner (65 +/- 16, 78 +/- 24, and 71 +/- 17 mEq/2 hours) whereas cimetidine, given every 6 hours, significantly (P less than .01) reduced meal-stimulated acid secretion (25 +/- 16, 27 +/- 20 and 31 +/- 15 mEq/2 hours, breakfast, lunch, and dinner, respectively) as compared with placebo (81 +/- 30, 76 +/- 25, and 66 +/- 16 mEq/2 hours, breakfast, lunch, and dinner, respectively).",Pharmacokinetics and pharmacodynamics of oral nizatidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895125/),[meq] / [2],66,79379,DB00585,Nizatidine
,12362922,apparent terminal elimination rate constant,The apparent terminal elimination rate constant for nizatidine in the pediatric subjects (0.58 +/- 0.8h(-1)) was virtually identical to that (0.54 +/- 0.13 h(-1)) previously reported from adult studies.,Single-dose pharmacokinetics of nizatidine (Axid) in children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12362922/),1/[h],0.58,94492,DB00585,Nizatidine
,12362922,apparent terminal elimination rate constant,The apparent terminal elimination rate constant for nizatidine in the pediatric subjects (0.58 +/- 0.8h(-1)) was virtually identical to that (0.54 +/- 0.13 h(-1)) previously reported from adult studies.,Single-dose pharmacokinetics of nizatidine (Axid) in children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12362922/),1/[h],0.54,94493,DB00585,Nizatidine
,1796603,Absolute bioavailability,"Absolute bioavailability was close to 100%, indicating that nizatidine has a negligible first-pass effect.",Pharmacokinetics of nizatidine in dogs and rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796603/),%,100,99953,DB00585,Nizatidine
,1796603,Bioavailability,"Bioavailability in rats was 72.4%, indicating a slight first-pass effect in rats.",Pharmacokinetics of nizatidine in dogs and rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796603/),%,72.4,99954,DB00585,Nizatidine
,26538490,flow rate,"The flow rate was set at 1.0 mL min(-1), and the effluent was monitored by UV detector at 280 nm FAM and 320 nm for NIZ and RAN.",An Efficient Ion-Pair Liquid Chromatographic Method for the Determination of Some H2 Receptor Antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26538490/),[ml] / [min],1.0,164152,DB00585,Nizatidine
,26538490,limits of detections,"The limits of detections and quantitations were 0.008-0.011 and 0.025-0.033 µg mL(-1), respectively.",An Efficient Ion-Pair Liquid Chromatographic Method for the Determination of Some H2 Receptor Antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26538490/),[μg] / [ml],0.008-0.011,164153,DB00585,Nizatidine
,26538490,limits of detections,"The limits of detections and quantitations were 0.008-0.011 and 0.025-0.033 µg mL(-1), respectively.",An Efficient Ion-Pair Liquid Chromatographic Method for the Determination of Some H2 Receptor Antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26538490/),[μg] / [ml],0.025-0.033,164154,DB00585,Nizatidine
,7912279,cell-to-medium concentration ratios,"The uptakes of cimetidine and nizatidine achieved equilibrium in 5 min with cell-to-medium concentration ratios of 12.0 and 3.5, respectively.","Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: contribution of type I system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912279/),,12.0,166574,DB00585,Nizatidine
,7912279,cell-to-medium concentration ratios,"The uptakes of cimetidine and nizatidine achieved equilibrium in 5 min with cell-to-medium concentration ratios of 12.0 and 3.5, respectively.","Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: contribution of type I system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912279/),,3.5,166575,DB00585,Nizatidine
,2888796,t1/2,Calculated pharmacokinetic variables in the elderly vs. the young were t1/2 = 1.9 vs.,"Nizatidine, and H2-receptor antagonist: disposition and safety in the elderly. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888796/),,1.9,167764,DB00585,Nizatidine
,2888796,CLp/f,"1.6 hr; CLp/f = 32 vs. 40 L/hr, and Vd beta/f = 1.2 vs. 1.3 L/kg.","Nizatidine, and H2-receptor antagonist: disposition and safety in the elderly. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888796/),[l] / [h],32,167765,DB00585,Nizatidine
,2888796,CLp/f,"1.6 hr; CLp/f = 32 vs. 40 L/hr, and Vd beta/f = 1.2 vs. 1.3 L/kg.","Nizatidine, and H2-receptor antagonist: disposition and safety in the elderly. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888796/),[l] / [h],40,167766,DB00585,Nizatidine
,2888796,Vd beta/f,"1.6 hr; CLp/f = 32 vs. 40 L/hr, and Vd beta/f = 1.2 vs. 1.3 L/kg.","Nizatidine, and H2-receptor antagonist: disposition and safety in the elderly. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888796/),[l] / [kg],1.2,167767,DB00585,Nizatidine
,2888796,Vd beta/f,"1.6 hr; CLp/f = 32 vs. 40 L/hr, and Vd beta/f = 1.2 vs. 1.3 L/kg.","Nizatidine, and H2-receptor antagonist: disposition and safety in the elderly. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888796/),[l] / [kg],1.3,167768,DB00585,Nizatidine
,7863246,bioavailability,"Antacid ingestion decreased the bioavailability of famotidine, ranitidine and cimetidine by 20-25%, and the bioavailability of nizatidine by 12%.",Drug interactions of H2-receptor antagonists. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7863246/),,12,179873,DB00585,Nizatidine
,2890459,absolute oral bioavailability,"The absolute oral bioavailability, relative to that after intravenous administration, was 98% +/- 14%.",Absorption studies of the H2-blocker nizatidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890459/),%,98,192484,DB00585,Nizatidine
,2892249,plasma half-life,The plasma half-life in each of the animal species was between 1 and 2 h and no accumulation of nizatidine or its metabolites was seen in rats or dogs after daily oral administration for long periods.,Pharmacology and toxicology of nizatidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892249/),h,1 and 2,195724,DB00585,Nizatidine
,2892251,elimination half-life,"Nizatidine had no significant effect on the hepatic elimination of diazepam, as characterized by its elimination half-life (mean +/- SD) of 35.3 +/- 24.2 h (control) and 37.3 +/- 18.3 h (+ nizatidine) or its total plasma clearance of 28.2 +/-12.0 ml/min (control) and 26.7 +/- 10.4 ml/min (+ nizatidine).",Lack of effect of nizatidine on drug metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892251/),h,35.3,195854,DB00585,Nizatidine
,2892251,elimination half-life,"Nizatidine had no significant effect on the hepatic elimination of diazepam, as characterized by its elimination half-life (mean +/- SD) of 35.3 +/- 24.2 h (control) and 37.3 +/- 18.3 h (+ nizatidine) or its total plasma clearance of 28.2 +/-12.0 ml/min (control) and 26.7 +/- 10.4 ml/min (+ nizatidine).",Lack of effect of nizatidine on drug metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892251/),h,37.3,195855,DB00585,Nizatidine
,2892251,total plasma clearance,"Nizatidine had no significant effect on the hepatic elimination of diazepam, as characterized by its elimination half-life (mean +/- SD) of 35.3 +/- 24.2 h (control) and 37.3 +/- 18.3 h (+ nizatidine) or its total plasma clearance of 28.2 +/-12.0 ml/min (control) and 26.7 +/- 10.4 ml/min (+ nizatidine).",Lack of effect of nizatidine on drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892251/),[ml] / [min],28.2,195856,DB00585,Nizatidine
,2892251,total plasma clearance,"Nizatidine had no significant effect on the hepatic elimination of diazepam, as characterized by its elimination half-life (mean +/- SD) of 35.3 +/- 24.2 h (control) and 37.3 +/- 18.3 h (+ nizatidine) or its total plasma clearance of 28.2 +/-12.0 ml/min (control) and 26.7 +/- 10.4 ml/min (+ nizatidine).",Lack of effect of nizatidine on drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892251/),[ml] / [min],26.7,195857,DB00585,Nizatidine
,2890666,terminal half-life,Neither ranitidine nor nizatidine had any significant effect on the hepatic elimination of D as characterized by its terminal half-life (mean +/- SD) of 35.3 +/- 24.2 hours (+ ranitidine: 30.1 +/- 9.9 hr; + nizatidine: 37.3 +/- 18.3 hr) or total plasma clearance of 28.2 +/- 12.0 mL/min (+ ranitidine: 26.5 +/- 7.9 mL/min; + nizatidine: 26.7 +/- 10.4 mL/min).,Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890666/),h,35.3,211889,DB00585,Nizatidine
,2890666,terminal half-life,Neither ranitidine nor nizatidine had any significant effect on the hepatic elimination of D as characterized by its terminal half-life (mean +/- SD) of 35.3 +/- 24.2 hours (+ ranitidine: 30.1 +/- 9.9 hr; + nizatidine: 37.3 +/- 18.3 hr) or total plasma clearance of 28.2 +/- 12.0 mL/min (+ ranitidine: 26.5 +/- 7.9 mL/min; + nizatidine: 26.7 +/- 10.4 mL/min).,Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890666/),h,30.1,211890,DB00585,Nizatidine
,2890666,terminal half-life,Neither ranitidine nor nizatidine had any significant effect on the hepatic elimination of D as characterized by its terminal half-life (mean +/- SD) of 35.3 +/- 24.2 hours (+ ranitidine: 30.1 +/- 9.9 hr; + nizatidine: 37.3 +/- 18.3 hr) or total plasma clearance of 28.2 +/- 12.0 mL/min (+ ranitidine: 26.5 +/- 7.9 mL/min; + nizatidine: 26.7 +/- 10.4 mL/min).,Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890666/),h,37.3,211891,DB00585,Nizatidine
,2890666,total plasma clearance,Neither ranitidine nor nizatidine had any significant effect on the hepatic elimination of D as characterized by its terminal half-life (mean +/- SD) of 35.3 +/- 24.2 hours (+ ranitidine: 30.1 +/- 9.9 hr; + nizatidine: 37.3 +/- 18.3 hr) or total plasma clearance of 28.2 +/- 12.0 mL/min (+ ranitidine: 26.5 +/- 7.9 mL/min; + nizatidine: 26.7 +/- 10.4 mL/min).,Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890666/),[ml] / [min],28.2,211892,DB00585,Nizatidine
,2890666,total plasma clearance,Neither ranitidine nor nizatidine had any significant effect on the hepatic elimination of D as characterized by its terminal half-life (mean +/- SD) of 35.3 +/- 24.2 hours (+ ranitidine: 30.1 +/- 9.9 hr; + nizatidine: 37.3 +/- 18.3 hr) or total plasma clearance of 28.2 +/- 12.0 mL/min (+ ranitidine: 26.5 +/- 7.9 mL/min; + nizatidine: 26.7 +/- 10.4 mL/min).,Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890666/),[ml] / [min],26.5,211893,DB00585,Nizatidine
,2890666,total plasma clearance,Neither ranitidine nor nizatidine had any significant effect on the hepatic elimination of D as characterized by its terminal half-life (mean +/- SD) of 35.3 +/- 24.2 hours (+ ranitidine: 30.1 +/- 9.9 hr; + nizatidine: 37.3 +/- 18.3 hr) or total plasma clearance of 28.2 +/- 12.0 mL/min (+ ranitidine: 26.5 +/- 7.9 mL/min; + nizatidine: 26.7 +/- 10.4 mL/min).,Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890666/),[ml] / [min],26.7,211894,DB00585,Nizatidine
exceeded,2892261,absolute oral bioavailability,"The absolute oral bioavailability of nizatidine exceeded 90%; the half-life (t1/2), plasma clearance (Clp), and volume of distribution (Vd) of iv nizatidine were 1.3 h, 461/h, and 1.21/kg, respectively.",A pharmacokinetic profile of nizatidine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892261/),%,90,215101,DB00585,Nizatidine
,2892261,half-life (t1/2),"The absolute oral bioavailability of nizatidine exceeded 90%; the half-life (t1/2), plasma clearance (Clp), and volume of distribution (Vd) of iv nizatidine were 1.3 h, 461/h, and 1.21/kg, respectively.",A pharmacokinetic profile of nizatidine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892261/),h,1.3,215102,DB00585,Nizatidine
,2892261,plasma clearance (Clp),"The absolute oral bioavailability of nizatidine exceeded 90%; the half-life (t1/2), plasma clearance (Clp), and volume of distribution (Vd) of iv nizatidine were 1.3 h, 461/h, and 1.21/kg, respectively.",A pharmacokinetic profile of nizatidine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892261/),1/[h],461,215103,DB00585,Nizatidine
,2892261,volume of distribution (Vd),"The absolute oral bioavailability of nizatidine exceeded 90%; the half-life (t1/2), plasma clearance (Clp), and volume of distribution (Vd) of iv nizatidine were 1.3 h, 461/h, and 1.21/kg, respectively.",A pharmacokinetic profile of nizatidine in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892261/),1/[kg],1.21,215104,DB00585,Nizatidine
,1820880,Cmax,"The results evidenced differences among the pharmacokinetic parameters of the two groups: the mean of Cmax was higher in the elderly than in the young (3.28 mg/ml against 2.23 mg/ml), the peak time was prolonged in the elderly (2.1 h against 1.00 h) and the AUC values were higher too (12.17 in the elderly and 7.99 in the young).",The effect of aging on the pharmacokinetics of nizatidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820880/),[mg] / [ml],3.28,231980,DB00585,Nizatidine
,1820880,Cmax,"The results evidenced differences among the pharmacokinetic parameters of the two groups: the mean of Cmax was higher in the elderly than in the young (3.28 mg/ml against 2.23 mg/ml), the peak time was prolonged in the elderly (2.1 h against 1.00 h) and the AUC values were higher too (12.17 in the elderly and 7.99 in the young).",The effect of aging on the pharmacokinetics of nizatidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820880/),[mg] / [ml],2.23,231981,DB00585,Nizatidine
,1820880,peak time,"The results evidenced differences among the pharmacokinetic parameters of the two groups: the mean of Cmax was higher in the elderly than in the young (3.28 mg/ml against 2.23 mg/ml), the peak time was prolonged in the elderly (2.1 h against 1.00 h) and the AUC values were higher too (12.17 in the elderly and 7.99 in the young).",The effect of aging on the pharmacokinetics of nizatidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820880/),h,2.1,231982,DB00585,Nizatidine
,1820880,peak time,"The results evidenced differences among the pharmacokinetic parameters of the two groups: the mean of Cmax was higher in the elderly than in the young (3.28 mg/ml against 2.23 mg/ml), the peak time was prolonged in the elderly (2.1 h against 1.00 h) and the AUC values were higher too (12.17 in the elderly and 7.99 in the young).",The effect of aging on the pharmacokinetics of nizatidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820880/),h,1.00,231983,DB00585,Nizatidine
,1820880,AUC,"The results evidenced differences among the pharmacokinetic parameters of the two groups: the mean of Cmax was higher in the elderly than in the young (3.28 mg/ml against 2.23 mg/ml), the peak time was prolonged in the elderly (2.1 h against 1.00 h) and the AUC values were higher too (12.17 in the elderly and 7.99 in the young).",The effect of aging on the pharmacokinetics of nizatidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820880/),,12.17,231984,DB00585,Nizatidine
,1820880,AUC,"The results evidenced differences among the pharmacokinetic parameters of the two groups: the mean of Cmax was higher in the elderly than in the young (3.28 mg/ml against 2.23 mg/ml), the peak time was prolonged in the elderly (2.1 h against 1.00 h) and the AUC values were higher too (12.17 in the elderly and 7.99 in the young).",The effect of aging on the pharmacokinetics of nizatidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820880/),,7.99,231985,DB00585,Nizatidine
,1820880,elimination half-life t1/2,Only the elimination half-life t1/2 was slightly higher in the elderly (1.8 h against 1.7 h in the young).,The effect of aging on the pharmacokinetics of nizatidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820880/),h,1.8,231986,DB00585,Nizatidine
,1820880,elimination half-life t1/2,Only the elimination half-life t1/2 was slightly higher in the elderly (1.8 h against 1.7 h in the young).,The effect of aging on the pharmacokinetics of nizatidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820880/),h,1.7,231987,DB00585,Nizatidine
,15723428,C(max),"Mean+/-SD C(max), T(max), AUC(0-->t), AUC(0-->infinity), and t1/2 were 2.96+/-0.54 and 3.28+/-0.68 microg/ml, 1.31+/-0.70 and 0.93+/-0.38 h, 9.04+/-1.66 and 9.03+/-1.94 microg x h/ml, 9.17+/-1.64 and 9.12+/-1.94 microg x h/ml, and 1.64+/-0.21 and 1.58+/-0.22 h for the generic and innovator formulation, respectively.",Bioequivalence of two oral formulations of nizatidine capsules in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15723428/),[μg] / [ml],2.96,263041,DB00585,Nizatidine
,15723428,T(max),"Mean+/-SD C(max), T(max), AUC(0-->t), AUC(0-->infinity), and t1/2 were 2.96+/-0.54 and 3.28+/-0.68 microg/ml, 1.31+/-0.70 and 0.93+/-0.38 h, 9.04+/-1.66 and 9.03+/-1.94 microg x h/ml, 9.17+/-1.64 and 9.12+/-1.94 microg x h/ml, and 1.64+/-0.21 and 1.58+/-0.22 h for the generic and innovator formulation, respectively.",Bioequivalence of two oral formulations of nizatidine capsules in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15723428/),[h·μg] / [ml],9.17,263042,DB00585,Nizatidine
,15723428,AUC(0-->t),"Mean+/-SD C(max), T(max), AUC(0-->t), AUC(0-->infinity), and t1/2 were 2.96+/-0.54 and 3.28+/-0.68 microg/ml, 1.31+/-0.70 and 0.93+/-0.38 h, 9.04+/-1.66 and 9.03+/-1.94 microg x h/ml, 9.17+/-1.64 and 9.12+/-1.94 microg x h/ml, and 1.64+/-0.21 and 1.58+/-0.22 h for the generic and innovator formulation, respectively.",Bioequivalence of two oral formulations of nizatidine capsules in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15723428/),[h·μg] / [ml],9.17,263043,DB00585,Nizatidine
,15723428,AUC(0-->infinity),"Mean+/-SD C(max), T(max), AUC(0-->t), AUC(0-->infinity), and t1/2 were 2.96+/-0.54 and 3.28+/-0.68 microg/ml, 1.31+/-0.70 and 0.93+/-0.38 h, 9.04+/-1.66 and 9.03+/-1.94 microg x h/ml, 9.17+/-1.64 and 9.12+/-1.94 microg x h/ml, and 1.64+/-0.21 and 1.58+/-0.22 h for the generic and innovator formulation, respectively.",Bioequivalence of two oral formulations of nizatidine capsules in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15723428/),[μg] / [ml],3.28,263044,DB00585,Nizatidine
,15723428,AUC(0-->infinity),"Mean+/-SD C(max), T(max), AUC(0-->t), AUC(0-->infinity), and t1/2 were 2.96+/-0.54 and 3.28+/-0.68 microg/ml, 1.31+/-0.70 and 0.93+/-0.38 h, 9.04+/-1.66 and 9.03+/-1.94 microg x h/ml, 9.17+/-1.64 and 9.12+/-1.94 microg x h/ml, and 1.64+/-0.21 and 1.58+/-0.22 h for the generic and innovator formulation, respectively.",Bioequivalence of two oral formulations of nizatidine capsules in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15723428/),[h·μg] / [ml],9.17,263045,DB00585,Nizatidine
,15723428,t1/2,"Mean+/-SD C(max), T(max), AUC(0-->t), AUC(0-->infinity), and t1/2 were 2.96+/-0.54 and 3.28+/-0.68 microg/ml, 1.31+/-0.70 and 0.93+/-0.38 h, 9.04+/-1.66 and 9.03+/-1.94 microg x h/ml, 9.17+/-1.64 and 9.12+/-1.94 microg x h/ml, and 1.64+/-0.21 and 1.58+/-0.22 h for the generic and innovator formulation, respectively.",Bioequivalence of two oral formulations of nizatidine capsules in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15723428/),[h·μg] / [ml],9.12,263046,DB00585,Nizatidine
,15723428,t1/2,"Mean+/-SD C(max), T(max), AUC(0-->t), AUC(0-->infinity), and t1/2 were 2.96+/-0.54 and 3.28+/-0.68 microg/ml, 1.31+/-0.70 and 0.93+/-0.38 h, 9.04+/-1.66 and 9.03+/-1.94 microg x h/ml, 9.17+/-1.64 and 9.12+/-1.94 microg x h/ml, and 1.64+/-0.21 and 1.58+/-0.22 h for the generic and innovator formulation, respectively.",Bioequivalence of two oral formulations of nizatidine capsules in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15723428/),h,1.64,263047,DB00585,Nizatidine
,15723428,t1/2,"Mean+/-SD C(max), T(max), AUC(0-->t), AUC(0-->infinity), and t1/2 were 2.96+/-0.54 and 3.28+/-0.68 microg/ml, 1.31+/-0.70 and 0.93+/-0.38 h, 9.04+/-1.66 and 9.03+/-1.94 microg x h/ml, 9.17+/-1.64 and 9.12+/-1.94 microg x h/ml, and 1.64+/-0.21 and 1.58+/-0.22 h for the generic and innovator formulation, respectively.",Bioequivalence of two oral formulations of nizatidine capsules in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15723428/),h,1.58,263048,DB00585,Nizatidine
,1972674,half-life,"The disposition of nizatidine (half-life, 1 1/2 hours; apparent serum clearance, 40 L/hr; renal clearance, 27 L/hr; and apparent volume of distribution, 1.4 L/kg) was similar in lactating and nonlactating women.",Secretion of nizatidine into human breast milk after single and multiple doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1972674/),h,1,265588,DB00585,Nizatidine
,1972674,apparent serum clearance,"The disposition of nizatidine (half-life, 1 1/2 hours; apparent serum clearance, 40 L/hr; renal clearance, 27 L/hr; and apparent volume of distribution, 1.4 L/kg) was similar in lactating and nonlactating women.",Secretion of nizatidine into human breast milk after single and multiple doses. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1972674/),[l] / [h],40,265589,DB00585,Nizatidine
,1972674,renal clearance,"The disposition of nizatidine (half-life, 1 1/2 hours; apparent serum clearance, 40 L/hr; renal clearance, 27 L/hr; and apparent volume of distribution, 1.4 L/kg) was similar in lactating and nonlactating women.",Secretion of nizatidine into human breast milk after single and multiple doses. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1972674/),[l] / [h],27,265590,DB00585,Nizatidine
,1972674,apparent volume of distribution,"The disposition of nizatidine (half-life, 1 1/2 hours; apparent serum clearance, 40 L/hr; renal clearance, 27 L/hr; and apparent volume of distribution, 1.4 L/kg) was similar in lactating and nonlactating women.",Secretion of nizatidine into human breast milk after single and multiple doses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1972674/),[l] / [kg],1.4,265591,DB00585,Nizatidine
,23836529,flow rate,"Chromatographic separation was performed on a Inertsil C18 column (150 mm × 4.6 mm, 5 µm) using isocratic elution by a mobile phase consisting of methanol/water (55:45) at a flow rate of 1.2 mL/min.",HPLC fluorescence method for the determination of nizatidine in human plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23836529/),[ml] / [min],1.2,270376,DB00585,Nizatidine
